References
- Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61:3–7.
- Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998;60:33–40.
- Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10:709–20.
- Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743–6.
- Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992;1:323–9.
- Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997;49:207–16.
- Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 2009;18:237–47.
- Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A. 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533–6.
- Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009;29:757–65.
- Shore N, Cookson MS, Gittelman MC. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int 2012;109:226–32.
- Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007;100:6–11.
- Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543–8.
- Schulman C, Alcaraz A, Berges R, Montorsi F, Teillac P, Tombal B. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100:1–5.
- Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750–7.